Tagraxofusp Clinical Trials
6 recruitingDrug
Phase 14Phase 24
Showing 1–6 of 6 trials
Recruiting
Phase 2
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Acute Myeloid Leukemia
Joshua Zeidner53 enrolled7 locationsNCT05442216
Recruiting
Phase 2
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Acute Myeloid Leukemia
Stemline Therapeutics, Inc.83 enrolled32 locationsNCT06456463
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 1
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosis
Karen Ballen, MD44 enrolled2 locationsNCT05233618
Recruiting
Phase 1Phase 2
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University20 enrolled1 locationNCT06561152
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770